Syndax Pharmaceuticals

About Syndax Pharmaceuticals

Syndax is a commercial stage oncology innovator focused on developing first-in-class therapies for areas of significant unmet need, such as acute leukemia and chronic graft-versus-host disease. Their mission is to advance targeted cancer treatments to help people with cancer live longer and better, adhering to scientific excellence and serving the patient community.

Products & Services

Revumenib (Revuforj®):A menin inhibitor approved in the U.S. in 2024 for the treatment of relapsed or refractory NPM1 mutated acute myeloid leukemia, with ongoing trials for other genetically defined acute leukemias and earlier lines of therapy.

Axatilimab:An anti-CSF-1R monoclonal antibody approved in the U.S. in 2024, with investigations into earlier lines of therapy, combination therapies, and potential indications like idiopathic pulmonary fibrosis (Phase 2 trial ongoing).

Entinostat (SNDX-275):Part of Syndax's treatment pipeline, though specific details on indications or approval status are not provided in the content.

Specialties

Acute Leukemia Treatments Chronic Graft-Versus-Host Disease Menin Inhibition Anti-CSF-1R Monoclonal Antibodies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Royalty Funding T: - FT: Royalty Funding	A: 350000000 MR: - FA: $350 million FAN: 350000000	D: 2024-11-04 FD: 2024-11-04	1 investors
2	RT: Royalty T: - FT: Royalty	A: 350000000 MR: - FA: $350 million FAN: 350000000	D: 2024-11-04 FD: 2024-11-04	1 investors
3	RT: Public Offering T: - FT: Public Offering	A: 230000000 MR: - FA: approximately $230.0 million FAN: 230000000	D: 2023-12-19 FD: 2023-12-19	5 investors
4	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: approximately $200.0 million FAN: 200000000	D: 2023-12-14 FD: 2023-12-14	5 investors
5	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: 150 million FAN: 150000000	D: 2023-12-14 FD: 2023-12-14	4 investors

Royalty Funding Latest

2024-11-04

$350.0M

1 investor (Pro only)

Royalty 2024-11-04

$350.0M

Public Offering 2023-12-19

$230.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dennis G. Podlesak

Chair of the Board of Directors

M

Michael A. Metzger

Chief Executive Officer and Director

M

Martin H. Huber, M.D.

Director

J

Jennifer Jarrett

Director

K

Keith A. Katkin

Director

P

Pierre Legault

Director

View 11 more team members with Pro

Unlock Full Team Directory

Recent News